YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Iovance Biotherapeutics (IOVA) shares ended the last trading session 31.5% higher at $14.45. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 34.5…
Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings…
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prost…
For Immediate Release Chicago, IL – September 16 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the…
September marks Prostate Cancer Awareness Month, putting renewed attention on one of the most common cancer manifestations affecting men. The American Cancer Society estimates that 333,830 men in the United States will be diagnosed with pr…
- JANX013 is a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific designed to further enhance the durability of anti-tumor immune responses in combination with Janux's PSMA-targeted T cell engager candidates - Study will ev…
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Quick Read Gold surged to $4,602 and crypto rallied on U.S. Treasury buyback plans while Monday futures traded lower entering the final week of August. Baird cut both CMG and DPZ to Neutral while UBS upgraded CLS to Buy, lifting its target…
Shares of Janux Therapeutics JANX have risen 19.1% over the past three months, driven by continued progress across its clinical pipeline and a series of upcoming catalysts. The company is making steady progress across its oncology and immu…
In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier. For the first half…
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurring i…
JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) JANX011 Phase 1 heal…
It can be hard to identify which small-cap biotech stocks will end up in the vast sea of failed trials, and which have the makings of something more viable. The screener behind this article is built to surface companies that are already ge…
In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index re…
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. "Today's news…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the most promising stocks on our list. TheFly reported on June 25 that Truist Securities…
By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance at the 2026 American Society o…
By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for…
Shares of Janux Therapeutics, Inc. (JANX) have gained 2.3% over the past four weeks to close the last trading session at $14.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts…
Janux Therapeutics JANX is making steady progress across its oncology and immunotherapy pipeline, led by its three proprietary tumor-activated core platforms, including Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulat…
Key Points Prosight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter. The value of the firm’s Nektar Therapeutics position rose…
On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics(NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…
Key Points Prosight bought 468,463 shares of GeneDx Holdings, estimated at $42.72 million based on average first-quarter 2026 prices. The quarter-end value of the position rose by $26.46 million, reflecting both trading and price moves. Th…
On May 15, 2026, Prosight Management disclosed a purchase of 468,463 shares of GeneDx Holdings(NASDAQ:WGS), an estimated $42.72 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago. These figures are adjusted for non-recurring it…
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in h…
Janux Therapeutics, Inc. (JANX) closed the last trading session at $14.62, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.…
SAN DIEGO, April 27, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue furthe…
Hospital operator Universal Health Services, Inc. UHS is set to report first-quarter 2026 results on April 27, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $5.3…
Hospital operator HCA Healthcare, Inc. HCA is set to report first-quarter 2026 results on April 24, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $7.19 per shar…
The S&P 500 Index ($SPX) (SPY) today is down -0.21%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.24%. June E-mini S&P futures (ESM26) are down -0.18%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.21%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.24%. June E-mini S&P futures (ESM26) are down -0.18%, and June E-mini Nas…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from Eli Lilly and OpenAI, as well as updates from Janux Thera…
-JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic…
Elevance Health, Inc. ELV is set to report its first-quarter 2026 results on April 22, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $10.61 per shareon revenues…